Target Price | JPY1,935.71 |
Price | JPY1,534.50 |
Potential |
26.15%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Astellas Pharma 2025 .
The average Astellas Pharma target price is JPY1,935.71.
This is
26.15%
register free of charge
JPY2,400.00
56.40%
register free of charge
JPY1,400.00
8.77%
register free of charge
|
|
A rating was issued by 15 analysts: 7 Analysts recommend Astellas Pharma to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2025 of
26.15%
register free of charge
|
Mar '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 1,603.67 | 1,801.84 |
5.60% | 12.36% | |
EBITDA Margin | 20.95% | 18.12% |
18.68% | 13.49% | |
Net Margin | 1.06% | 4.12% |
83.41% | 288.52% |
13 Analysts have issued a sales forecast Astellas Pharma 2025 . The average Astellas Pharma sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Astellas Pharma EBITDA forecast 2025. The average Astellas Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Astellas Pharma Analysts have issued a net profit forecast 2025. The average Astellas Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | 9.50 | 41.43 |
82.49% | 336.11% | |
P/E | 37.28 | |
EV/Sales | 1.95 |
6 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Astellas Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Astellas Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.